wiki pageCreated: 2026-04-02T07:19:11By: crosslink-v3Quality:
50%✓ SciDEXID: wiki-proteins-erk1-protein
📖 Wiki Page
redirect586 wordssynced 2026-04-02
ERK1 Protein
Overview
ERK1 (Extracellular Signal-Regulated Kinase 1), also known as mitogen-activated protein kinase 3 (MAPK3), is a serine/threonine protein kinase that belongs to the mitogen-activated protein kinase (MAPK) family. The protein is encoded by the MAPK3 gene located on human chromosome 16. ERK1 functions as a critical signaling node that transduces extracellular stimuli into intracellular responses regulating gene expression, protein synthesis, cell proliferation, differentiation, and cell survival. Its closely related homolog ERK2 (MAPK1) shares approximately 84% amino acid identity with ERK1, and both proteins typically function redundantly in most cellular contexts, though they may exhibit distinct roles in certain neuronal populations and developmental stages.
Function/Biology
ERK1 operates as a downstream effector within the canonical Ras/Raf/MEK/ERK signaling cascade, one of the most evolutionarily conserved signal transduction pathways. Upon activation by growth factors, neurotrophic factors, or other extracellular signals binding to receptor tyrosine kinases (RTKs), the pathway is initiated at the plasma membrane where Ras becomes activated. This recruits and activates RAF kinase, which subsequently phosphorylates and activates dual-specificity kinase MEK1/2. MEK proteins then phosphorylate ERK1/2 at conserved threonine and tyrosine residues within the activation loop (T202/Y204 in ERK1), triggering conformational changes that expose the active site and fully activate catalytic activity.
...
ERK1 Protein
Overview
ERK1 (Extracellular Signal-Regulated Kinase 1), also known as mitogen-activated protein kinase 3 (MAPK3), is a serine/threonine protein kinase that belongs to the mitogen-activated protein kinase (MAPK) family. The protein is encoded by the MAPK3 gene located on human chromosome 16. ERK1 functions as a critical signaling node that transduces extracellular stimuli into intracellular responses regulating gene expression, protein synthesis, cell proliferation, differentiation, and cell survival. Its closely related homolog ERK2 (MAPK1) shares approximately 84% amino acid identity with ERK1, and both proteins typically function redundantly in most cellular contexts, though they may exhibit distinct roles in certain neuronal populations and developmental stages.
Function/Biology
ERK1 operates as a downstream effector within the canonical Ras/Raf/MEK/ERK signaling cascade, one of the most evolutionarily conserved signal transduction pathways. Upon activation by growth factors, neurotrophic factors, or other extracellular signals binding to receptor tyrosine kinases (RTKs), the pathway is initiated at the plasma membrane where Ras becomes activated. This recruits and activates RAF kinase, which subsequently phosphorylates and activates dual-specificity kinase MEK1/2. MEK proteins then phosphorylate ERK1/2 at conserved threonine and tyrosine residues within the activation loop (T202/Y204 in ERK1), triggering conformational changes that expose the active site and fully activate catalytic activity.
Once activated, phosphorylated ERK1 translocates to the nucleus where it phosphorylates and activates multiple transcription factors including Elk1, c-Fos, and CREB. ERK1 also phosphorylates cytoplasmic substrates including RSK kinases and protein phosphatase 2A inhibitors, amplifying and diversifying downstream signaling. The pathway is tightly regulated through phosphatase activity, particularly by dual-specificity phosphatases (DUSPs) and serine/threonine phosphatases that dephosphorylate and inactivate ERK1. This negative feedback ensures temporal precision and prevents excessive pathway activation.
Role in Neurodegeneration
ERK1/2 signaling dysfunction is increasingly implicated in multiple neurodegenerative diseases. In Alzheimer's disease, dysregulation of ERK1/2 phosphorylation has been observed in affected brain regions, with evidence suggesting both excessive and insufficient pathway activation in different cellular contexts. Amyloid-beta accumulation and tau hyperphosphorylation can aberrantly activate ERK1/2, contributing to neuroinflammation and neuronal dysfunction. Conversely, impaired ERK1/2 signaling compromises neurotrophic factor responses essential for neuronal survival and synaptic plasticity.
In Parkinson's disease models, ERK1/2 dysregulation occurs following alpha-synuclein aggregation and neuroinflammatory insults. Reduced ERK1/2 signaling impairs cellular stress responses and dopaminergic neuron survival. In ALS, abnormal ERK1/2 activation has been detected in motor neurons harboring mutant SOD1, contributing to excitotoxicity and apoptosis. Huntington's disease shows complex ERK1/2 dysregulation, with mutant huntingtin protein interfering with normal MAPK pathway signaling, impairing neuronal survival signals and contributing to striatal neuronal vulnerability.
Molecular Mechanisms
At the molecular level, ERK1 dysfunction in neurodegeneration involves several mechanisms. Pathological protein accumulation (amyloid-beta, tau, alpha-synuclein, mutant huntingtin) can activate ERK1/2 excessively through pattern recognition receptors and neuroinflammatory pathways, triggering maladaptive transcriptional responses including pro-apoptotic and pro-inflammatory gene expression. Simultaneously, neurotrophic signaling may become impaired, reducing basal ERK1/2 activation necessary for survival signaling. Oxidative stress and mitochondrial dysfunction impair both upstream activation (through RTK signaling defects) and DUSP-mediated regulation of ERK1/2, causing pathway dysregulation.
Clinical/Research Significance
Modulating ERK1/2 signaling represents a promising therapeutic strategy for neurodegenerative diseases. MEK inhibitors and ERK1/2 inhibitors are being investigated to reduce pathological ERK1/2 hyperactivation. Conversely, approaches enhancing ERK1/2-dependent survival signaling through neurotrophic factors or receptor agonists are under development. Understanding tissue-specific and context-dependent roles of ERK1 versus ERK2 may enable selective therapeutic targeting. Animal models of neurodegeneration demonstrate that optimizing ERK1/2 pathway activity—neither excessive nor deficient—provides neuroprotection.